Type of information: Private placement
Company: Audentes Therapeutics (USA - CA)
Amount: $231.4 million
Funding type: private placement
- • On January 29, 2018, Audentes Therapeutics announced the closing of its previously announced underwritten public offering of 6,612,500 shares of its common stock at a price to the public of $35.00 per share before underwriting discounts and commissions, which included the exercise in full by the underwriters of their option to purchase 862,500 additional shares of common stock. After giving effect to the full exercise of the option to purchase additional shares, the gross proceeds, before deducting the underwriting discounts and commissions and other offering expenses payable by Audentes, increased to approximately $231.4 million.
- The shares were offered by Audentes pursuant to a shelf registration statement (File No. 333-219797) on Form S-3 that was filed by Audentes with the Securities and Exchange Commission on August 8, 2017 and declared effective by the SEC on August 23, 2017, and a related automatically effective registration statement filed pursuant to Rule 462(b) of the Securities Act of 1933, as amended (File No. 333-222680).
- • On January 24, 2018, Audentes Therapeutics announced the pricing of its underwritten public offering of 5,750,000 shares of its common stock at a price to the public of $35.00 per share before underwriting discounts and commission. The offering is expected to close on January 29, 2018, subject to customary closing conditions. BofA Merrill Lynch, Cowen and Leerink Partners are acting as joint book-running managers for the offering. Wedbush PacGrow is acting as co-manager.
- • On January 23, 2018, Audentes Therapeutics announced that it intends to offer $150.0 million of its common stock in an underwritten public offering. In addition, Audentes intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of its common stock offered in the public offering at the public offering price less the underwriting discounts and commissions. All of the shares will be offered and sold by Audentes. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. BofA Merrill Lynch, Cowen and Leerink Partners are acting as joint book-running managers for the offering. Wedbush PacGrow is acting as co-manager.
Therapeutic area: Rare diseases - Genetic diseases